


DMPK


IN VITRO ADMET

OUR SERVICES

- **Absorption**
 - » Caco-2
 - » MDCK-MDR1
- **Distribution**
 - » Protein binding
 - » K_{bb}
 - » RBC
- **Clearance**
 - » Clint in different matrix
 - » Phenotyping
- **Drug-Drug Interaction**
 - » IC₅₀
 - » IC₅₀ shift
 - » K_i
 - » Induction
- **Metabolite ID**
 - » GSH trapping
 - » Metabolite ID
- **In Vitro Genotoxicity**
 - » Mini-Ames
- **Physical-Chemical Property**
 - » Solubility
 - » LogD
- **Customized Assays**




IN VITRO PERMEATION MODEL



IN VITRO CYP INDUCTION MODEL


CUSTOMIZED ASSAY

INTRACELLULAR DRUG UPTAKE AND METABOLISM (HepG2 cells, dosed at 50 nM)



IN VITRO ADMET SERVICES

IN VITRO ADMET STUDIES ENGAGED IN DISCOVERY PROGRAMS AND IND ENABLING




75,000+ compounds screened for clients world-wide since 2008

PROJECTS/STUDIES	ONCOLOGY 1	ONCOLOGY 2	CNS 1	CNS 2	CNS 3	CNS 4	IND-ENABLING (CASE)
Solubility	258	75	55	46	27	11	
Liver Microsomal Stability	120	13	159	120	22	10	3
CYP Inhibition	120	195	94	15	14	7	3
Plasma Stability			59				
Hepatocyte or S9 Stability				20			
Protein Binding	40	13	108		19	13	3
Caco-2	7	16					5
MDCK-MDR1			96	70	38	13	
CYP TD1			11				
CYP Induction							3
Mini-Ames		7					

ASSESSMENT OF ENZYME-BASED DRUG-DRUG INTERACTION

K_i DETERMINATION FOR QUINIDINE ON CYP2D6
(Using GraphPad Prism 5)



CYP INDUCTION DETERMINED USING HUMAN HEPATOCYTES
(3 Donors)

